NeoPhore Names Michael Shih CEO
NeoPhore Limited, a company specializing in small molecule neoantigen immuno-oncology therapies, has appointed Michael Shih as its Chief Executive Officer (CEO) and as a member of the Board of Directors, effective immediately. This appointment marks a significant milestone as the…